198 related articles for article (PubMed ID: 19220425)
1. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.
Khademi M; Bornsen L; Rafatnia F; Andersson M; Brundin L; Piehl F; Sellebjerg F; Olsson T
Eur J Neurol; 2009 Apr; 16(4):528-36. PubMed ID: 19220425
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.
Mellergård J; Edström M; Vrethem M; Ernerudh J; Dahle C
Mult Scler; 2010 Feb; 16(2):208-17. PubMed ID: 20007431
[TBL] [Abstract][Full Text] [Related]
3. Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis.
Khademi M; Stol D; Olsson T; Wallström E
Eur J Neurol; 2008 Mar; 15(3):309-12. PubMed ID: 18190511
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients.
Wen SR; Liu GJ; Feng RN; Gong FC; Zhong H; Duan SR; Bi S
J Neuroimmunol; 2012 Mar; 244(1-2):94-6. PubMed ID: 22329905
[TBL] [Abstract][Full Text] [Related]
5. The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients.
O'Connell KE; Mok T; Sweeney B; Ryan AM; Dev KK
Autoimmunity; 2014 Dec; 47(8):505-11. PubMed ID: 24974887
[TBL] [Abstract][Full Text] [Related]
6. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.
Khademi M; Wallström E; Andersson M; Piehl F; Di Marco R; Olsson T
J Neuroimmunol; 2000 Mar; 103(2):202-10. PubMed ID: 10696916
[TBL] [Abstract][Full Text] [Related]
7. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
[TBL] [Abstract][Full Text] [Related]
8. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
9. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A
J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
[TBL] [Abstract][Full Text] [Related]
11. Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Simpson S; Stewart N; van der Mei I; Otahal P; Charlesworth J; Ponsonby AL; Blizzard L; Dwyer T; Pittas F; Gies P; Taylor B
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):200-7. PubMed ID: 24790215
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
13. Expression of costimulatory molecules and cytokines in CSF and peripheral blood mononuclear cells from multiple sclerosis patients.
Monteyne P; Van Antwerpen MP; Sindic CJ
Acta Neurol Belg; 1999 Mar; 99(1):11-20. PubMed ID: 10218088
[TBL] [Abstract][Full Text] [Related]
14. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism.
Ramos-Cejudo J; Oreja-Guevara C; Stark Aroeira L; Rodriguez de Antonio L; Chamorro B; Diez-Tejedor E
J Clin Immunol; 2011 Aug; 31(4):623-31. PubMed ID: 21491095
[TBL] [Abstract][Full Text] [Related]
15. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
Oreja-Guevara C; Ramos-Cejudo J; Aroeira LS; Chamorro B; Diez-Tejedor E
BMC Neurol; 2012 Sep; 12():95. PubMed ID: 22989378
[TBL] [Abstract][Full Text] [Related]
16. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis.
Iaffaldano P; Ruggieri M; Viterbo RG; Mastrapasqua M; Trojano M
Brain Behav Immun; 2014 Jan; 35():176-81. PubMed ID: 23994630
[TBL] [Abstract][Full Text] [Related]
17. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
18. Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients.
Patanella AK; Zinno M; Quaranta D; Nociti V; Frisullo G; Gainotti G; Tonali PA; Batocchi AP; Marra C
J Neurosci Res; 2010 Apr; 88(5):1106-12. PubMed ID: 19885866
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
20. In vitro restoration of post-operatively decreased IFN-gamma levels after cardiac surgery and its effect on pro- and anti-inflammatory mediators.
Franke A; Lante W; Markewitz A; Weinhold C
J Surg Res; 2006 Dec; 136(2):266-72. PubMed ID: 17054992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
